HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, K Articles by Greenough, A Search for Related Content PubMed PubMed Citation Articles by Johnson, K Articles by Greenough, A

Treatment of neonatal abstinence syndrome

¹ Children Nationwide Regional Neonatal Intensive Care Centre, Department of Child Health, King’s College Hospital, London SE5 9RS, UK
² The Hurley Clinic, Kennington Lane, London SE11 4HJ, UK

Correspondence to:
Correspondence to:
Dr Johnson, Department of Child Health, 4th floor, Ruskin Wing, King’s College Hospital, London SE5 9RS, UK:
kathryn.2.johnson{at}kcl.ac.uk

ABSTRACT
Neonatal abstinence syndrome (NAS) is suffered by infants withdrawing from substances on which they have become physically dependent after in utero exposure. They may require prolonged treatment and spend weeks or even months in hospital. A wide range of drugs have been used to treat NAS. The efficacy of few, however, have been adequately investigated. Evidence suggests that opioids are the most appropriate, at least in infants exposed to diamorphine or methadone. In all "head to head" trials, diazepam has been shown to be ineffective. Morphine and methadone are currently the most commonly prescribed opioids to treat NAS, but randomised trials have not been undertaken to determine which is the more beneficial. Many infants with NAS have been exposed to multiple substances in utero. Further research is required into whether a single opiate or a multiple drug regimen is the best option for such patients.

Keywords: neonatal abstinence syndrome; drug abuse

This article has been cited by other articles:

				W. K. Kraft, E. Gibson, K. Dysart, V. S. Damle, J. L. LaRusso, J. S. Greenspan, D. E. Moody, K. Kaltenbach, and M. E. Ehrlich Sublingual Buprenorphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Trial Pediatrics, September 1, 2008; 122(3): e601 - e607. [Abstract] [Full Text] [PDF]

				Z. Kassim and A. Greenough Effects of substance abuse during pregnancy The Journal of the Royal Society for the Promotion of Health, September 1, 2005; 125(5): 212 - 214. [PDF]